Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

NCT02972333 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

EGFR-TKI Resistant Mutation
Nonsmall Cell Lung Cancer
AZD9291
Brain Metastases

Interventions

DRUG: AZD9291 80mg oral each day
RADIATION: Radiation therapy

Sponsor

Shandong Cancer Hospital and Institute

Collaborators

[object Object]